Search Results - "Sarhan, Dareen"

Abstract LB217: Ascorbic acid rescues antitumor immune response by reversing hypoxia-induced CD8+T cell dysfunction by Jafarzadeh, Nazli, Gaur, Pankaj, Sarhan, Dareen, Shobaki, Nour, Traboulsi, Wael, Ramlaoui, Zainab, Verma, Vivek, Gupta, Seema, Khleif, Samir N.

“…Growing evidence suggests that hypoxia is one of the most important phenomena of solid tumors that supports tumor progression as well as therapeutic…”
Get full text

Abstract 2881: Proper priming of T cells is crucial for the anti-tumor effect of mPTX-35, an anti-TNFRSF25 agonist antibody by Sarhan, Dareen, Rabah, Lara, Tahiliani, Vikas, Trinh, Anh M., Jasuja, Rahul R., Dixon, Eric P., Seavey, Matthew, Verma, Vivek, Gupta, Seema, Khleif, Samir N.

“…TNFRSF25, also known as Death Receptor 3 (DR3), is a cell surface receptor of the tumor necrosis factor receptor superfamily (TNFRSF) which is expressed on T…”
Get full text

Abstract LB339: PARP inhibition reprograms CD8 T cells, enhancing their function and generation of prolonged memory, leading to greater anti-tumor immune response by Traboulsi, Wael, Kundu, Subhadip, Gaur, Pankaj, Ramlaoui, Zainab, Sarhan, Dareen, Shobaki, Nour, Lee, Jacob, Jafarzadeh, Nazli, Barry, Simon T., Valge-Archer, Viia E., Verma, Vivek, Gupta, Seema, Khleif, Samir N.

“…Olaparib is the most widely studied third-generation PARP inhibitor (PARPi) in clinical practice with a significant clinical outcome in BRCA deficient tumors…”
Get full text